Status:
ENROLLING_BY_INVITATION
CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborating Sponsors:
Royal Free Hospital NHS Foundation Trust
Royal Brompton & Harefield NHS Foundation Trust
Conditions:
Melanoma Stage III or IV
Eligibility:
All Genders
18+ years
Brief Summary
People who develop a type of skin cancer known as 'melanoma' are often treated with immunotherapy. The type of immunotherapy used for patients with melanoma is known as Immune Checkpoint Inhibitors (I...
Detailed Description
Primary aim • To establish the feasibility of conducting a study to investigate late cardiac side effects caused by immunotherapy in patients with melanoma in order to generate data to support a large...
Eligibility Criteria
Inclusion
- Written informed consent
- Age 18 years or older
- Confirmed diagnosis of melanoma
- Stage IIB or IIC or stage III or stage IV melanoma
- Previous immunotherapy with immune-checkpoint inhibitors (anti PD-(L)1 +/- anti CTLA-4) for melanoma
- On standard of care surveillance, at 2 to 10+ years following the completion of immunotherapy treatment
Exclusion
- Medical or psychological condition that would preclude informed consent.
- Known contraindications to MRI, such as claustrophobia, pregnancy, or indwelling metallic implant which is not MR conditional
- Current active treatment with systemic therapy for any malignancy.
- Active treatment with systemic therapy for any malignancy started after the completion of immunotherapy for melanoma.
- Subjects unable to comply with the study or sample schedule.
- Planned participation in a drug trial receiving investigational agents.
Key Trial Info
Start Date :
September 26 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06605833
Start Date
September 26 2025
End Date
September 30 2026
Last Update
October 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Marsden NHS Foundation Trust
London, United Kingdom, SW6 3JJ